A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

ClinicalTrials.gov ID: NCT07355062

Public ClinicalTrials.gov record NCT07355062. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.

Study identification

NCT ID: NCT07355062
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Renibus Therapeutics, Inc.; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Interventions

Veverimer Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 12, 2026
Primary completion: May 31, 2027
Completion: May 31, 2027
Last update posted: Sep 3, 2026

2026 – 2027

United States locations

U.S. sites: 23
U.S. states: 12
U.S. cities: 23

Facility	City	State	ZIP	Site status
Study Site	Chula Vista	California	91910	Recruiting
Study Site	Los Angeles	California	90022	Recruiting
Study Site	Sacramento	California	95817	Recruiting
Study Site	San Diego	California	92111	Recruiting
Study Site	Aurora	Colorado	80045	Recruiting
Study Site	Edgewater	Florida	32132	Recruiting
Study Site	Margate	Florida	33063	Recruiting
Study Site	Miami Springs	Florida	33166	Recruiting
Study Site	Orlando	Florida	32806	Recruiting
Study Site	Augusta	Georgia	30904	Recruiting
Study Site	Boise	Idaho	83706	Recruiting
Study Site	Chubbuck	Idaho	83201	Recruiting
Study Site	Idaho Falls	Idaho	83401	Recruiting
Study Site	Chicago	Illinois	60643	Recruiting
Study Site	Indianapolis	Indiana	46202	Recruiting
Study Site	Louisville	Kentucky	40205	Recruiting
Study Site	Kansas City	Missouri	64111	Recruiting
Study Site	Fresh Meadows	New York	11365	Recruiting
Study Site	New York	New York	10016	Recruiting
Study Site	Winston-Salem	North Carolina	27103	Recruiting
Study Site	Fort Worth	Texas	76110	Recruiting
Study Site	Houston	Texas	77054	Recruiting
Study Site	San Antonio	Texas	78212	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07355062, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 3, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07355062 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →